Posted by Michael Wonder on 01 Jun 2020
Orphazyme initiates rolling submission of new drug application for arimoclomol with US FDA in Niemann-Pick disease type C
29 May 2020 - EMA marketing authorisation application submission expected in H2 2020.
Orphazyme today announces it has initiated the submission of its new drug application for a rolling review by the US FDA for arimoclomol, an investigational Heat-Shock Protein amplifier, for the treatment of Niemann-Pick disease type C.
